Stock Movers: Oracle, American Express, Eli Lilly

Oracle shares declined after the company's long-range financial outlook, which projected $225 billion in annual revenue by fiscal 2030, failed to meet investor expectations for AI infrastructure growth. In contrast, American Express reported stronger-than-anticipated earnings and raised its full-year guidance, attributing the success to robust demand for its recently revamped Platinum credit card. Concurrently, Eli Lilly's stock fell following former President Trump's remarks suggesting a potential significant reduction in the price of the diabetes drug Ozempic, a development that could materially impact the future profitability of the dominant players in the rapidly growing diabetes drug market.

Analysis

Oracle (ORCL) shares declined following its long-range financial outlook, which projected $225 billion in annual revenue by fiscal 2030, including $144 billion from cloud infrastructure. This suggests investors had higher expectations for AI infrastructure growth, despite the company addressing profitability concerns by stating a 35% gross margin for AI infrastructure projects.

Conversely, American Express (AXP) reported stronger-than-expected earnings, driven by robust demand for its recently revamped Platinum credit card, with US account acquisitions doubling. The firm subsequently raised the lower end of its full-year guidance, now expecting revenue growth of 9% to 10% and earnings per share between $15.20 and $15.50.

Eli Lilly (LLY) and Novo Nordisk (NVO) shares fell sharply after former President Trump suggested the price of the diabetes drug Ozempic could drop from approximately $1,000 to $150 per month. This potential regulatory intervention poses a significant threat to the profitability of both companies, which dominate a market projected to reach $95 billion by 2030.

Key Decisions for Investors

• Investors should closely monitor Oracle's AI infrastructure execution and profitability, as market expectations for growth remain elevated.
• Consider American Express's strong product-driven momentum, but assess the sustainability of premium card acquisition and competitive pressures.
• Evaluate the significant regulatory and political risks impacting Eli Lilly and Novo Nordisk, particularly potential drug pricing interventions that could compress future margins in the diabetes market.